结直肠癌的抗表皮生长因子受体治疗路在何方？

Where now for anti-EGF receptor therapies in colorectal cancer?

机构信息

Department of Pathophysiology and Repair, School of Bioscience, Cardiff, University, Museum Avenue, Cardiff, CF10 3AX, UK.

出版信息

Expert Rev Anticancer Ther. 2011 Oct;11(10):1543-53. doi: 10.1586/era.11.143.

DOI:10.1586/era.11.143

PMID:21999128

Abstract

Current US FDA-approved monoclonal antibodies targeting the EGF receptor (EGFR) include cetuximab and panitumumab. In this article, we discuss the clinical evidence concerning the use of monoclonal antibodies targeting the EGFR in the setting of advanced colorectal cancer and the emergence of predictive molecular biomarkers. In addition, we also consider the evidence surrounding the evolution of anti-EGFR-resistance mechanisms evoked by targeted anti-EGFR therapy and potential therapeutic strategies that may counteract resistant tumor growth.

摘要

目前，美国食品和药物管理局（FDA）批准的针对表皮生长因子受体（EGFR）的单克隆抗体包括西妥昔单抗和帕尼单抗。本文讨论了关于在晚期结直肠癌中使用针对 EGFR 的单克隆抗体的临床证据，以及预测性分子生物标志物的出现。此外，我们还考虑了靶向抗 EGFR 治疗引发的抗 EGFR 耐药机制演变的证据，以及可能对抗耐药肿瘤生长的潜在治疗策略。